Scope Fluidics develops innovative projects in the field of diagnostics and health care.
The company was established in 2010 in the Institute of Physical Chemistry of the Polish Academy of Sciences with the aim of creating solutions for medicine based on microfluidic technologies. The company cooperates with the academia, and integrates the points of view of medicine and business to develop innovative solutions with a high market potential.
Within the Capital Group, Scope Fluidics has its own experts in finance, administration and legal issues that are used by the companies which belong to the Group. Scope Fluidics provides the source of funding, as it transfers to special purpose entities the money needed to cover the cost of R&D works and provides the so-called own resources for EU funding. Companys business model provides for the development and business verification of a project, followed by the establishment of a special purpose entity within which the whole project is developed.
Scope Fluidics includes two special purpose entities: Curiosity Diagnostics Sp. z o.o. and Bacteromic Sp. z o.o.
During the years 2012-2015, Curiosity Diagnostics worked on the technology of rapid analysis of the genetic material of bacterial and viral pathogens. The outcome of these works is currently used in the delivery of the PCR|ONE project. On the other hand, Bacteromic developed its own system, named after the company. This project will combine innovative microfluidic technology with traditional microbiological methods of drug resistance testing in order to obtain information on pathogens drug resistance and select the best treatment that is tailored to patients individual needs.
Since 2017, Scope Fluidics S.A. has been listed on the NewConnect stock exchange.
Read more: www.scopefluidics.com